(Z)-4-(4-(trifluoromethyl)phenoxy)-O-(4-(4-fluorobenzoyl)benzamidoxime) | 1138697-97-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-4-(4-(trifluoromethyl)phenoxy)-O-(4-(4-fluorobenzoyl)benzamidoxime)
• 英文别名: (Z)-4-(4-(trifluoromethyl)phenoxy)-O-(4-fluorobenzoyl)benzamidoxime；[(E)-[amino-[4-[4-(trifluoromethyl)phenoxy]phenyl]methylidene]amino] 4-fluorobenzoate
• CAS: 1138697-97-8
• 化学式: C₂₁H₁₄F₄N₂O₃
• 分子量: 418.347
• InChiKey: JHZXGTJOUPKDRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (Z)-4-(4-(trifluoromethyl)phenoxy)-O-(4-(4-fluorobenzoyl)benzamidoxime) 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 以92%的产率得到5-(4-fluorophenyl)-3-(4-(4-(trifluoromethyl)phenoxy)-phenyl)-1,2,4-oxadiazole
  参考文献：
  名称：

  ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME

  摘要：

  本发明的实施例提供了针对青霉素结合蛋白或其他重要细胞靶标的新型抗菌剂。本文描述的化合物用于抑制细菌的生长（繁殖等）的方法也得到提供。各种实施例对革兰氏阳性细菌表现出活性，如某些肠球菌和金黄色葡萄球菌菌株。

  公开号：

  US20100261673A1
• 作为产物：
  描述：

  4-(4-(trifluoromethyl)phenoxy)benzonitrile 在 羟胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 26.0h， 生成 (Z)-4-(4-(trifluoromethyl)phenoxy)-O-(4-(4-fluorobenzoyl)benzamidoxime)
  参考文献：
  名称：

  Discovery of a New Class of Non-β-lactam Inhibitors of Penicillin-Binding Proteins with Gram-Positive Antibacterial Activity

  摘要：

  Infections caused by hard-to-treat methicillin-resistant Staphylococcus aureus (MRSA) are a serious global public-health concern, as MRSA has become broadly resistant to many classes of antibiotics. We disclose herein the discovery of a new class of non-beta-lactam antibiotics, the oxadiazoles, which inhibit penicillin-binding protein 2a (PBP2a) of MRSA. The oxadiazoles show bactericidal activity against vancomycin-and linezolid-resistant MRSA and other Gram-positive bacterial strains, in vivo efficacy in a mouse model of infection, and have 100% oral bioavailability.

  DOI：

  10.1021/ja500053x

文献信息

• ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME
  申请人：Mobashery Shahriar

  公开号：US20100261673A1

  公开（公告）日：2010-10-14

  Embodiments of the present invention provide novel antibacterials that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.

  本发明的实施例提供了针对青霉素结合蛋白或其他重要细胞靶标的新型抗菌剂。本文描述的化合物用于抑制细菌的生长（繁殖等）的方法也得到提供。各种实施例对革兰氏阳性细菌表现出活性，如某些肠球菌和金黄色葡萄球菌菌株。
• [EN] ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS ANTIBACTÉRIENS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV NOTRE DAME DU LAC

  公开号：WO2009041972A1

  公开（公告）日：2009-04-02

  Embodiments of the present invention provide novel antibactehals that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.

  本发明实施例提供了针对青霉素结合蛋白或其他重要细胞靶点的新型抗菌剂。本文描述的化合物用于抑制细菌的生长（繁殖等）的方法也提供了。各种实施例对革兰氏阳性细菌表现出活性，例如某些肠球菌和金黄色葡萄球菌菌株。
• US9045442B2
  申请人：——

  公开号：US9045442B2

  公开（公告）日：2015-06-02
• Discovery of a New Class of Non-β-lactam Inhibitors of Penicillin-Binding Proteins with Gram-Positive Antibacterial Activity
  作者：Peter I. O’Daniel、Zhihong Peng、Hualiang Pi、Sebastian A. Testero、Derong Ding、Edward Spink、Erika Leemans、Marc A. Boudreau、Takao Yamaguchi、Valerie A. Schroeder、William R. Wolter、Leticia I. Llarrull、Wei Song、Elena Lastochkin、Malika Kumarasiri、Nuno T. Antunes、Mana Espahbodi、Katerina Lichtenwalter、Mark A. Suckow、Sergei Vakulenko、Shahriar Mobashery、Mayland Chang

  DOI：10.1021/ja500053x

  日期：2014.3.5

  Infections caused by hard-to-treat methicillin-resistant Staphylococcus aureus (MRSA) are a serious global public-health concern, as MRSA has become broadly resistant to many classes of antibiotics. We disclose herein the discovery of a new class of non-beta-lactam antibiotics, the oxadiazoles, which inhibit penicillin-binding protein 2a (PBP2a) of MRSA. The oxadiazoles show bactericidal activity against vancomycin-and linezolid-resistant MRSA and other Gram-positive bacterial strains, in vivo efficacy in a mouse model of infection, and have 100% oral bioavailability.